Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

NCT03244072 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60000

Last updated 2025-09-25

No results posted yet for this study

Summary

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Conditions

  • Endophthalmitis

Interventions

DRUG

Moxifloxacin

Intracameral injection

DRUG

Placebo

intracameral injection

Sponsors & Collaborators

  • Jason Ahee, M.D.

    lead INDUSTRY

Principal Investigators

  • Jason Ahee, M.D. · Zion Therapeutics, LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2030-10-31
Completion
2031-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03244072 on ClinicalTrials.gov